Navigation Links
Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Date:4/7/2013

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH).

Both CTEPH and PAH are life-threatening diseases.  CTEPH is a form of pulmonary hypertension in which blood clots and thromboembolic occlusion of pulmonary vessels leads to increased pressure in the pulmonary arteries.  PAH is a disease characterized by elevated pressure in the pulmonary arteries.

"We are pleased that the FDA has granted priority review of the riociguat NDA for two distinct forms of pulmonary hypertension," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "This milestone reinforces our commitment to advancing treatment options for cardio-pulmonary diseases, and brings us one step closer to potentially providing the first pharmacological treatment for inoperable or persistent/recurrent CTEPH and a new treatment option for PAH."

The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA aims to complete its review within six months of the 60-day filing receipt of the NDA submission (eight months total), rather than the standard 12-month review cycle.

The NDA submission is supported by data from two global Phase III studies of riociguat CHEST-1 and PATENT-1. Data from these two studies were presented in October 2012 at CHEST, the annual meeting of the American College of Chest Physicians (ACCP). Both Phase III studies on ri
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
4. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
5. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
6. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
7. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
11. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... Healthcare Conference on Wednesday, September 10. ... will provide an update on the company, beginning at ... Time).   A webcast of the presentation ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... HANOVER, N.J., Dec. 6, 2010 The Novartis ... demonstrated substantial disease control and tumor reduction in ... or had become refractory after an autologous stem ... Phase II clinical trial presented today(1). ...
... 6, 2010 Wells Fargo Practice Finance, formerly known ... preferred provider for optometric practice and equipment financing for ... affinity relationship through the AOA,s Member Advantage Program will ... for practice acquisition, start-up and expansion projects, along with ...
Cached Medicine Technology:Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 2Wells Fargo Practice Finance Named Preferred Provider to the American Optometric Association's Member Advantage Program 3
(Date:8/31/2014)... Richmond, CA (PRWEB) August 31, 2014 ... program of the California State Library, celebrates 30 ... and their families. Since its inception, California’s Library ... a million Californians learn to read and write. ... this volunteer-based program, the state is launching a ...
(Date:8/31/2014)... 2014 The severity of menopausal symptoms ... in menopause is expert in helping patients find ... from uncomfortable symptoms with the latest treatment options, including ... a variety of alternative treatments and products that can ... options may fall outside of what can be called ...
(Date:8/31/2014)... Spain Sunday 31 August 2014: Drinking tea reduces ... 000 people presented at ESC Congress today by Professor ... you have to choose between tea or coffee it,s ... important components of our way of life. Their effects ... past with sometimes divergent results. We investigated the effects ...
(Date:8/30/2014)... 2014: Local anaesthetic is as safe and effective for ... to results of the FRANCE 2 registry presented at ... , Dr Chopard said: "Numerous studies have shown that ... severe symptomatic aortic stenosis who are at very high ... The number of TAVI procedures in France and around ...
(Date:8/30/2014)... Orlando, Florida (PRWEB) August 31, 2014 ... gait walking and how a mobility device can help in ... now available for free download from the website that contains ... medical doctor for this site. , The articles deal with ... mobility device like a walking cane can help in making ...
Breaking Medicine News(10 mins):Health News:California Library Literacy Services Celebrates 30th Anniversary 2Health News:California Library Literacy Services Celebrates 30th Anniversary 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:Information Articles on Gait Problems from Walking-Canes.Net 2
... of Medicine (IOM) recently released a study, The Future ... calls for new and expanded roles for nurses in ... education for all nurses and allowing nurses to practice ... It advocates overhauling state scope of practice acts and ...
... was diagnosed in 2007 with acute multiple myeloma, a form ... troubles all those who receive an upsetting diagnosis. The way ... however, was different. Barrager drew upon his engineering and management ... is sharing his insights with hospitals and doctors in his ...
... Steven Reinberg HealthDay Reporter , MONDAY, Nov. ... pandemic H1N1 flu last year in California, more than ... California Department of Public Health researchers report. , ... to occur at similar rates as with seasonal influenza, ...
... News) -- Military veterans with psychiatric illnesses are at ... The greatest risk is among males with bipolar disorder ... researchers at the U.S. Department of Veterans Affairs and ... Overall, bipolar disorder (the least common diagnosis at 9 ...
... , MONDAY, Nov. 1 (HealthDay News) -- Any ... removed from play until evaluated by a physician who ... a new position statement issued by the American Academy ... recommendations directed at policymakers who develop procedures to be ...
... MONDAY, Nov. 1 (HealthDay News) -- Stroke patients are more ... the weekend instead of a weekday, regardless of the severity ... analyzed data from almost 21,000 stroke patients admitted to 11 ... their first stroke were included in the study. Seven ...
Cached Medicine News:Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 2Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 3Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 4Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 5Health News:ACP's response to the IOM's report the future of nursing: Leading change, advancing health 6Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 2Health News:Management science guru, surviving cancer, offers hope to fellow sufferers, doctors 3Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 2Health News: Pandemic H1N1 Flu Hit Kids Hard in 2009 3Health News:Bipolar Disorder Tied to High Suicide Risk in Veterans 2Health News:Concussion Should Sideline Athletes: Neurologists 2Health News:Weekend Admissions Worse for Stroke Victims: Study 2
... Compact and durable, the Medelec ... Whether your choice of a smaller ... your need to take your testing ... Notebook is the solution. The 2, ...
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... Myoquick 1200/1400/1800 units are based ... adopt the ISA 100x EP ... can select input units with ... 1002 EP), 4 channels (ISA ...
Sierra II power & efficiency plus. Sierra II report generator with automatic sentence generation creates the one-minute report. Complete 2/4 channel EMG/NCV/EP....
Medicine Products: